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Introduction
The pharmacological treatment of migraine may be acute or
preventive, and patients who experience frequent severe
headaches often require both approaches. The preventive
treatment for migraine includes beta-blockers, antidepres-
sants, calcium channel antagonists, serotonin antagonists,
non-steroid anti-inflammatory drugs (NSAIDs), riboflavin at
high doses and anticonvulsivant drugs. The large variety of
mechanisms of action of these drugs suggests that there are
a number of key points where drugs can reduce or prevent
the beginning of migraine attacks. Circumstances that war-
rant preventive treatment include: two or more attacks per
month that produce disability that lasts two or more days,
and contraindication to or inefficacy of symptomatic med-
ication [1]. On the other hand, prophylactic therapy should
be provided when abortive medications are assumed more
than twice per week, and in special circumstances such as
hemiplegic migraine or rare headache attacks producing pro-
found disruption or risk of permanent neurological injury [2].
Preventive medications should be started at low dosages
and increased slowly until therapeutic effects develop or
until the ceiling dosage for other indications is reached. For
example, tricyclic anti-depressants are used for depression
at dosages of 100–200 mg/day, while 20–30 mg/day may be
effective for migraine. Sodium valproate at 500–750 mg/day
can reduce migraine frequency, while higher dosages may
be necessary to effectively treat epilepsy and mania [2].
A full therapeutic trial, to evaluate the efficacy in pre-
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Abstract Anti-epileptic drugs are
employed for the prophylactic treat-
ment of migraine. Valproic acid and
its sodium salt (divalproex) have
been shown to be effective in pre-
venting migraine in double-blind
placebo-controlled studies.
Gabapentin and lamotrigine have
also been proposed for migraine pro-
phylaxis, but more extensive studies
are needed to confirm their effica-
cies. The main mechanism of action
of anti-epileptic drugs is the inhibi-
tion of the sodium channel to induce
a depolarization, preventing the high,
frequent action potentials typically
excited by convulsive attacks.
Moreover, valproate and gabapentin
increase brain concentrations of
GABA and, probably, inhibit the
degradation of GABA. Other pro-
posed mechanisms of action for val-
proate are a direct effect on neuronal
membranes and a reduction of exci-
tatory transmission by aspartate.
Valproate, at the recommended dose
of 500 mg twice daily, is well toler-
ated. The more frequent unwanted
effects associated with almost all
drugs of this class are weight gain,
drowsiness, dizziness and tremor.
Topiramate has recently been pro-
posed for the treatment of unrespon-
sive, high frequency migraine, taking
into account both the GABA and glu-
tamatergic mechanisms of action.
Key words Antiepileptic drugs •
Prophylactic treatment • Migraine •
Headache
Received: 13 November 2000
Accepted in revised form: 5 April 2001
14
venting migraine attacks, may take 3–6 months. In con-
trolled clinical trials, efficacy is often first noted after four
weeks and continues to increase for three months. It is not
uncommon for patients to be treated with a new preventive
medication for 1–2 weeks without effect and for the treat-
ment to be prematurely discontinued with both patient and
physician believing it was not effective [2].
To obtain maximal benefit from preventive medication,
the patient should not overuse analgesics or ergot deriva-
tives. In addition, oral contraceptives, hormonal replace-
ment therapy or vasodilating drugs such as nifedipine or
nitroglycerin may interfere with preventive drugs [2].
Recently, sodium valproate and other anticonvulsive
drugs have been more widely employed in preventive treat-
ment of migraine with good results. These drugs reduce the
firing response of neurons by acting on membrane ion chan-
nels or by acting on the GABA system. We do not know the
mode of action of these drug in preventing migraine.
Therefore, clinical evidence precedes the pharmacological
explanation. This implies that the evaluation of prophylactic
treatments for migraine needs to be carried out with care,
and that results should be analyzed taking into account the
lack of pharmacological basis for this therapy (Table 1).
In this review, we discuss the use of anti-epileptic drugs
in the preventive treatment of migraine attacks.
Sodium valproate
Sodium valproate is a classic anti-epileptic drug used since
1978. Its chemical structure is a simple branched-chain car-
boxylic acid. At therapeutic concentrations, valproate
inhibits sustained repetitive firing induced by depolarization
of mouse cortical or spinal cord neurons. The action is sim-
ilar to that of both phenytoin and carbamazepine, and
appears to be mediated by a prolonged recovery of voltage-
activated Na+ channels from inactivation [3].
Another probable mechanism that may contribute to val-
proate’s antiseizure action involves metabolism of gamma-
aminobutyric acid (GABA). The increase of brain GABA
concentrations depends on inhibition of both GABA amino-
transferase and succinic dehydrogenase, enzymes involved
in the synthesis and degradation of GABA. Selective
increases of GABA have been reported to occur in synapto-
somes, primarily in areas of high GABA activity after val-
proate administration. On the other hand, valproate inhibits
GABA re-uptake and reduces glutamate by activating glu-
tamic acid decarboxylase.
The enhancement of GABA activity in the brain, from
increased GABA synthesis and decreased GABA degrada-
tion, has been assumed to be the mechanism of action in pre-
venting migraine attacks [4]. Moreover, divalproex sodium
acts on the brain serotonin system by enhancing the GABA-
mediated inhibition of serotonin neurons of the dorsal raphe
area and raising the threshold of the onset of migraine [5].
Finally, this drug prevents vasodilatation during
migraine attacks [4].
Oral absorption is rapid, and occurs within 1–4 h. Peak
serum concentrations range from 50 to 100 µg/ml and the
volume of distribution is 0.130–0.23 l/kg. Protein binding is
91% and cerebrospinal fluid levels reach 10% of plasma
concentrations. Elimination half-life ranges from 8 to 17
hours, and extensive hepatic metabolism is followed by
renal excretion. Approximately 1.8%–3.2% of the adminis-
tered dose is excreted without modification, while 7% is
excreted in the bile within 7 h of administration.
Well-recognized adverse effects are thrombocytopenia,
hemorrhage, red cell aplasia, tremor, ataxia, fatigue, seda-
tion, abdominal cramps, dizziness, sedation, confusion,
Table 1 Mechanisms of action of sodium valproate and new anti-epileptic drugs
Anti-epileptic drug Mechanism of action
Gabapentin Stimulation of GABA turnover 
GABA mimetic
Lamotrigine Inhibition of glutamate release 
Blockade of voltage-sensitive channels
Tiagabine Reversible inhibition of GABA uptake
Topiramate Potentiation of GABA
Antagonism of AMPA receptors
Inhibition of carbonic anhydrase
Sodium valproate Inhibition of GABA uptake and GABA aminotransferase
Stimulation of brain GABA synthesis
Inhibition of voltage-sensitive channels
GABA, gaba-aminobutyric acid
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headache, nausea, diarrhea, alopecia and weight gain. In a
long-term study of sodium valproate therapy (48–60
months), almost all patients gained weight whereas only
14% experienced tremors [6, 7].
Concurrent use of primidone and valproic acid may
result in severe central nervous system depression. Aspirin,
erythromycin or felbamate may increase valproic acid toxi-
city (CNS depression). Fosphenytoin, acyclovir, imipenem,
isoniazid, phenobarbital and rifampicin may result in altered
valproate levels. 
For migraine headache prophylaxis, 500–1000 mg/kg
day in divided doses was used by Klapper in a dose-
response study that showed no improvement in activity up
doses of 1000 mg/day (Table 2) [8].
Clinical studies
In a series of 200 patients, divalproex sodium decreased
migraine frequency and severity in 80% of cases [5]. In a
series of 163 cases, Ghose found that in a 3-year follow-up
divalproex sodium was well tolerated, and retention rate for
tolerability was similar between placebo and treatment [6].
To asses the efficacy of sodium valproate as a prophy-
lactic agent in migraine headache, a prospective randomized
study was conduced in adult patients who previously
derived no significant benefit from most conventional pro-
phylactic therapy for migraine [9]. Twenty-seven patients
with a diagnosis of migraine with aura or migraine without
aura from a headache clinic received low dose sodium val-
proate for 3 months. Therapy response was defined as 50%
or greater reduction in the frequency of headache, and 71%
patients improved within 4–6 weeks. Plasma drug level
monitoring helped to identify four noncompliers. Clinical
improvement (percentage reduction in the frequency of
migraine attacks) was inversely correlated with plasma drug
levels at 13–24 months and daily dose of valproate. Patients
who did not respond to low dosage valproate were unlikely
to benefit from further increases in dosage [6, 9]. 
In a recently study, sodium valproate was used intra-
venously for the acute treatment of migraine attacks. A
group of 32 female patients with a history of refractory
severe headache received 500 mg sodium valproate.
Valproate was well tolerated with minimal side effects. After
one hour, complete relief was recorded in 8 patients, and at
24 hours 12 patients referred complete pain relief. Only one
patient referred transient somnolence [10].
In another study the efficacy and tolerability of repetitive
intravenous sodium valproate and intravenous dihydroergo-
tamine (DHE) in intractable migraine were examined [11].
Intravenous sodium valproate was as effective as intra-
venous DHE in breaking intractable migraine attacks, but it
was associated with less adverse events. In conclusion, these
studies suggest that valproate may be used along with other
migraine abortives. 
Gabapentin
Gabapentin is amino acid structurally related to GABA and
possesses GABA-mimetic properties.
Gabapentin increases the release of GABA by a not
completely known mechanism. Gabapentin inhibits the
neural synthesis of L-glutamate, a mechanism that may be
useful in chronic migraine treatment. In fact, the mecha-
nism that transforms episodic migraine into chronic
migraine may be linked to hyperalgesia and related neuro-
plastic changes, by the action of excitatory amino acids,
chiefly the ones acting at N-methyl D-aspartate (NMDA)
receptors [12].
Gabapentin is absorbed from the gastrointestinal tract
and has a bioavailability of 50%–60%, depending on dose.
Bioavailability is not influenced by food. Peak serum levels
occur 1–3 h after oral administration. The drug is not bound
by plasma proteins and does not appear to be metabolized.
All absorbed dose is excreted unchanged in the urine. The
terminal elimination half-life of gabapentin ranges between
5 and 7 hours.
Table 2 Clinical studies with valproic acid for migraine treatment
Reference Dosage (mg/day) IHS n Efficacy
Mathew ‘95 500–1000 1.1 200 48%
Ghose ‘98 500–1000 1.2 36 50%–71%
Robbins ‘00 500 1.1 32 62%
Klapper ‘97 500, 1000, 1500 1.1 176 45%
IHS, International Headache Society classification; 1.1, migraine without aura; 1.2, migraine with aura
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The most frequent adverse effects of gabapentin are
somnolence, dizziness, ataxia, nystagmus, skin rash, nausea,
vomiting, tremor, blurred vision and slurred speech.
The dosage for migraine treatment is 1550–2700 mg/day
with 65% improvement [12].
Anti-epileptic dosage of gabapentin is 900–1800 mg/day
in three administrations.
No interactions with other anticonvulsants have been
reported. Concurrent use of gabapentin and antacids may
result in decreased gabapentin effectiveness.
In a study 63 patients, with migraine with or without
aura, gabapentin (1200 mg/day) was well tolerated and
reduced the use of symptomatic drugs and the frequency of
headache. The authors concluded that gabapentin has a ther-
apeutic action in the prophylactic treatment of migraine [13].
Lamotrigine
Lamotrigine is a phenyltriazine derivative that blocks volt-
age-sensitive sodium channels and stabilizes neuronal mem-
branes, leading to the inhibition of neuronal release of the
excitatory neurotransmitter glutamate. Lamotrigine is well
absorbed after oral administration. Its oral bioavailability is
approximately 98%. Peak plasma levels are reached in 1–4 h
after dosing. Lamotrigine is approximately 55% protein-
bound. The volume of distribution ranges from 0.9 to 1.4
l/kg. The drug is primarily excreted in the urine as an N-glu-
curonide conjugate. Only 2% is excreted in the feces. The
most frequent adverse effects of lamotrigine are fatigue,
ataxia, dizziness, headache, diplopia and the rare, but severe,
Stevens-Johnson syndrome or toxic epidermal necrolysis. 
Oral doses of 200–500 mg/day are effective and well tol-
erated; 150–200 mg/day is used in concomitant valproic
acid therapy for anticonvulsive treatment, while 100 mg/day
is recommended for the prophylaxis of migraine headache.
Concurrent use of lamotrigine and valproic acid or ser-
traline may result in lamotrigine toxicity and increased risk
of epidermal necrolysis. Primidone, methosuximide, oxcar-
bamazepine, phenytoin, carbamazepine, phenobarbital,
phenytoin and acetaminophen may result in reduced lamot-
rigine effectiveness.
Clinical studies
The efficacy of lamotrigine (100 mg/day) was evaluated in
a controlled clinical trial for the prevention of migraine with
aura in 24 patients affected by high frequency migraine. The
patients took lamotrigine for 3 months. In the 21 patients
who completed the study, the attacks were completely abol-
ished at the third month of treatment [14]. 
In another controlled clinical trial, 13 patients suffering
from migraine with aura and 2 patients with aura but with-
out migraine were treated with lamotrigine. The dosage was
gradually increased in steps of 25 mg/day to 100 mg/day,
depending on the patient’s aura symptoms and tolerability.
The study concluded that lamotrigine is effective in pre-
venting migraine aura symptoms and in influencing
migraine headache frequency [15].
In a randomized, double-blind study, lamotrigine was
shown to be superior to placebo in reducing migraine attacks
in 110 patients. Lamotrigine therapy was started at the full
dosage of 200 mg/day but, because of the high incidence of
skin rashes, a slow dose-escalation was introduced: 25
mg/day for 2 weeks, 50 mg/day for 2 weeks, and finally 200
mg/day. Attack rates were reduced from baseline means of
3.6 per month on lamotrigine and 4.4 on placebo to 3.2 and
3.0, respectively, during the last month of treatment.
Improvements were greater on placebo. These changes, not
statistically significant, indicated that lamotrigine is ineffec-
tive for migraine prophylaxis (Table 3) [16].
These studies outline that lamotrigine is a first-choice drug
for the treatment of migraine with aura with high frequency of
attacks. Additionally, studies regarding SUNCT (short-last-
ing, unilateral, neuralgiform headache attacks with conjuncti-
val injection and tearing) treatment suggest that the patho-
genetic mechanism of migraine with aura likely involves the
excitatory aminoacids [15–17]. Lamotrigine was effective in
four cases with SUNCT syndrome [17, 18]. Lamotrigine was
the first effective attempt to treat the SUNCT syndrome.
Given the infrequency of this syndrome, it is difficult to orga-
nize a large clinical trial on this disease, and authors should be
encouraged to refer to the treatments for this syndrome.
In conclusion, the efficacy of lamotrigine for migraine
prophylaxis has not yet been completely demonstrated and
results are summarized in Table 3.
Table 3 Clinical studies with lamotrigine for migraine treatment
Reference Dose (mg/day) IHS n Efficacy
D’Andrea ‘99 100 1.2 24 100%
Lampl, ‘99 100 1.2 15 +++
Steiner, ‘97 25–200 1.1 110 Equivalent to placebo
D’Andrea ‘00 100–150 SUNCT 2 100%
IHS, International Headache Society; 1.1, migraine without aura; 1.2, migraine with aura
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Tiagabine 
Tiagabine, a bis(3-methyl-2 thienyl) derivative of nipecotic
acid, is a GABA inhibitor used for the treatment of partial
epilepsy. Tiagabine induces a significant elevation of extra-
cellular brain GABA levels in studies involving awake rats.
Peak serum concentrations of tiagabine usually occur
within 40 min after oral administration and are conditioned
by enterohepatic circulation. The drug is 98%
protein–bound and is metabolized in the liver. The elimina-
tion half-life range from 4 to 7 h. 
Tiagabine appears to be well tolerated. Predominant
adverse reactions include sedation, dizziness, memory
impairment, emotional fleeting, asthenia and tremor. 
Concurrent use of tiagabine and carbamazepine, pheny-
toin and phenobarbital decreased tiagabine efficacy because
of the induction of tiagabine metabolism, whereas the steady
state pharmacokinetics of digoxin or the mean daily serum
levels are not affected.
Clinical studies
In a clinical trial, 36 patients were treated with tiagabine
[19]. All patients suffered from migraine with or without
aura, according to IHS diagnostic criteria. Tiagabine thera-
py was initiated at 4 mg/day for 1 week, then increased to 4
mg twice daily. Patients were re-evaluated after 1 month of
therapy, and the doses were adjusted. Adverse events were
experienced in 12 patients, resulting in the discontinuation
of therapy in 9 of them. This study suggested that tiagabine
is an effective medication for migraine prophylaxis [19]. 
Topiramate
Topiramate is a sulfamate-substituted monosaccharide with
anti-epileptic activity. Recently, it has been shown to be
effective in neuropathic pain refractory to conventional
medical treatment. The mechanism of action includes mem-
brane-potential stabilization, increased GABA activity,
decreased glutamate activity and carbonic acid anhydrase
inhibition. 
Topiramate is readily absorbed following oral adminis-
tration with peak plasma concentration achieved about 2 h
after a dose; a relevant enterohepatic circulation is also pre-
sent. Bioavailability is not affected by the presence of food.
The volume of distribution is 0.6–0.8 l/kg and in women is
half that in men. The drug is metabolized in the liver and
eliminated chiefly in urine, both unmodified and as metabo-
lites. Plasma half-life is about 21 h. Steady state levels are
reached within 4–8 days, and drug elimination is impaired
by liver and renal insufficiency. The recommended doses for
seizure range between 200 and 400 mg/day. Topiramate
plasma concentrations were closely related to dosage, and
there were no significant interactions between topiramate
and other anti-epileptics. The following adverse events are
related to topiramate in 5% or more of patients: ataxia,
impaired concentration, confusion, dizziness, fatigue, pares-
thesia, somnolence and abnormal thinking. Topiramate may
also cause agitation and emotional lability (which may man-
ifest as abnormal behavior) and depression. Less common
adverse effects include amnesia, anorexia, aphasia, diplopia,
nausea, nystagmus, speech disorder, alteration of the sense
of taste, abnormal vision and weight loss. Topiramate
increases the risk of nephrolithiasis, especially in people
with a predisposition.
Clinical studies
Thirty patients aged 18–65 years with an IHS diagnosis of
migraine with or without aura were randomized to topiramate
(n=5) or placebo (n=15) after completing a 4-week baseline
phase [20]. Patients were treated over 6 weeks with 25
mg/day. Then, the dose was increased to a maximum of 100
mg, followed by a 12-week maintenance phase. The 50%
responder rate was significantly higher in the topiramate vs.
placebo group (46.7% vs. 6.7%, p=0.035). The most common
adverse events reported in the topiramate group were pares-
thesia, diarrhea, altered taste, and somnolence.
Wheeler and Carrazzana studied 15 consecutive cluster-
headache patients (3 unremitting from onset, one cluster-tic,
11 episodic) [21]. Six women and 9 men, with a median age
of 44.8 years, participated. The duration of headache ranged
from 1 week to 36 months. Topiramate appeared to be effec-
tive for cluster headache. The mean time to remission induc-
tion was 1.8 weeks in 11 patients. One patient even achieved
a steroid taper that had not been achieved before. Only one
patient was non-compliant and lost to follow-up. Two
patients dropped out of the study due to drowsiness. The
researchers concluded that topiramate was safe, well-tolerat-
ed and efficacious in the treatment of cluster headache [21].
In a double-blind, randomized, placebo-controlled study,
138 patients were treated with topiramate, which was found
to be efficacious in the prophylaxis of episodic migraine
[22]. Di Trapani et al. [23] evaluated a 3-month treatment
with topiramate as prophylaxis for migraine in 20 patients.
The preliminary results revealed a significant reduction in
the frequency and intensity of attacks, and no patients with-
drew because of side effects [23]. Similar results were
reported by Randall et al. in a retrospective study [24]. It
was also studied the effect of topiramate on weight in
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migraine and chronic daily headache with dosages ranging
from 50 to 800 mg/day. Treatment of headache with topira-
mate was associated with loss of weight [25].
In conclusion, these results suggest that topiramate is
effective in the prophylactic treatment of migraine.
Conclusions
The goals of preventive treatment are to optimize the qual-
ity of life for patients. The medications used to prevent
migraine fall into two major categories. First-line drugs
have high efficacy and include β-blockers, tricyclic antide-
pressants, calcium-channel blockers such as flunarizine,
and divalproex sodium. This category also includes drugs
with lower demonstrated efficacy such as selective sero-
tonin reuptake inhibitors (SSRIs), verapamil, nimodipine
and NSAIDs. Second-line, high efficacy drugs include
pizotifen, monoamino-oxidase inhibitors and drugs with
unproved or low efficacy, including cyproheptadine, lithi-
um and phenytoin. This category also includes new anti-
epileptic drugs.
The choice of a preventive drug must involve the accu-
rate evaluation of the clinical characteristics of the patients,
with attention to their age, sex, life style and co-morbidity.
In fact, only a complete evaluation of these parameters can
allow a correct evaluation of the best risk-to-benefit ratio for
the individual patient and take advantage of the side-effect
profile of the drug (Table 4).
A woman of childbearing potential should be on ade-
quate contraception before starting migraine medication.
However, some women who are pregnant or who are
attempting to become pregnant may still require preventive
medication. In these cases, the preventive treatment should
take into account the potential teratogenic risk compared to
the therapeutic benefit.
An underweight patient is a candidate for medication
that increases appetite, such as cyproheptadine, flunarizine
or tricyclic antidepressants (TCA) [25, 26]. In contrast, a
young woman with dietary problems should avoid these
drugs. Moreover, the type of employment should be evalu-
ated, because TCA, flunarizine and pizotifen can impair
attention and create dangerous situations for those who
drive or use machines.
Comorbidity and coexisting diseases can provide thera-
peutic opportunities in the choice of a drug, but in the same
way they impose therapeutic limitations. In the case of coex-
isting hypertension or angina, β-blockers and verapamil
may be considered effective for the treatment of both dis-
eases. Patients with depression should be treated successful-
ly with TCA or SSRIs, and migraneurs suffering from
seizures can be treated with divalproex sodium or other anti-
epileptic drugs.
On the other hand, patients may have diseases that con-
traindicate some drugs. For example, β-blockers such as flu-
narizine should be used carefully in patients with depres-
sion. TCA and neuroleptics, used in acute treatment in emer-
gency wards, can lower seizure threshold and should be
used with caution in epileptic migraneurs [2, 26]. 
Preventive medications are considered to be effective
when the reduction of the number of headaches is over 50%
[2]. The anti-epileptic drugs that we have reported in this
paper have been studied to detect this goal, and results are
often encouraging, even if not conclusive. Some of these
drugs, such as valproate and flunarizine, are certainly of
Table 4 Preventive therapy and comorbidity
Drug Efficacy Side effects Relative contraindications Recognised clinical indications
Beta-blockers 4+ 2+ Asthma, depression, CHF, Hypertension, angina
Raynaud’s disease, diabetes
Verapamil 2+ 1+ Constipation hypotension Migraine with aura, 
hypertension, angina, asthma
Tricyclic 4+ 2+ Mania, urinary retention, Other pain, depression, 
antidepressants heart block anxiety, insomnia
Selective serotonin 2+ 1+ Mania Depression, OCD
reuptake inhibitors
MAO-I 4+ 4+ Unreliable patients Refractory depression
Divalproex sodium 4+ 2+ Liver disease, Mania, epilepsy, 
and valproate bleeding disorders anxiety disorders
MAO-I, monoamino-oxidase I; CHF, chronic heart failure; OCD, obsessive compulsive disorders
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first-choice in the prevention of migraine attacks, whereas
other drugs such as lamotrigine, gabapentin and topiramate
are useful in resistant headaches or in neuropathic pain syn-
dromes.
The main goal we have is the improvement of the quali-
ty of life of our patients, and these newer drugs or these new
indications can enlarge our possibility to find the best drug
for the single patient. 
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